parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.04 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in neutrophils	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	25 Parkinson's papers of 441	0.57
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 5793

receipt 5801: SORL1 in dopamine neurons, braak

power: full sample -0.13 (p 0.597, n 18), 95% CI -0.57 to +0.36. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.18 (p 0.465, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.17 (p 0.493, n 18). could be the mix.
skeptic: leave-one-out range -0.27 to -0.05, sign flips 0; without severely affected donors -0.13 (p 0.597, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SORL1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 5800: SORL1 in microglia, braak

power: full sample +0.14 (p 0.591, n 18), 95% CI -0.35 to +0.57. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.08 (p 0.741, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.16 (p 0.532, n 18). could be the mix.
skeptic: leave-one-out range +0.01 to +0.30, sign flips 0; without severely affected donors +0.14 (p 0.591, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SORL1 in microglia.

case closed: nothing better to follow up.

loading the receipts